Sorrento's R&D wa ni idojukọ lori imotuntun awakọ ni COVID-19, itọju alakan, iṣakoso irora ni kikun ati awọn aarun autoimmune

Awọn eto bọtini	Ifarahan	Preclinical	Igbese I	Igbese II	Ipele III/Pivotal	FDA Approval
Awọn eto COVID-19
COVISTIX™ (aisan ayẹwo) Dekun Antijeni igbeyewo 0%* Aṣẹ Lilo pajawiri (EUA) ni Mexico (COFEPRIS), Brazil (ANVISA), ati CE Ti samisi ni Yuroopu COVIMARK™ (aisan ayẹwo) Dekun Antijeni igbeyewo 0%* Ohun elo ti a fi silẹ ni AMẸRIKA ati Kanada fun Aṣẹ Lilo pajawiri (EUA) COVISHIELD™ (itọju) Antibody Neutralizing (IN) ni Awọn Alaisan ati Awọn Alabojuto 40%* COVISHIELD™ (itọju) Antibody Neutralizing (IV) ni Awọn Alaisan ati Awọn Alabojuto 20%* FUJOVEE™ (Abivertinib) COVID-19 to lagbara ni Awọn alaisan ICU 82%* Idanwo pataki ni isunmọtosi imukuro FDA OQORY™ (COVI-MSC) ARDS nitori COVID-19 ni Awọn alaisan ICU 82%* Idanwo pataki ni Ilu Brazil Mpro Olugbeja (ògùn ẹnu) Alatako-ọlọjẹ 40%* Omicron mRNA ajesara Ajesara 20%*
Awọn eto bọtini	Ifarahan	Preclinical	Igbese I	Igbese II	Ipele III/Pivotal	FDA Approval
ajẹsara
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) Ibo ori 20%* FUJOVEE™ (Abivertinib) lupus 20%* FUJOVEE™ (Abivertinib) MS 20%* FUJOVEE™ (Abivertinib) GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* * Ni Ajọṣepọ pẹlu Lee's Pharm ni Ilu China PD-L1 (STI-3031)** obo akàn 82%* ** Ni AMẸRIKA ati ni ajọṣepọ pẹlu ImmuneOncia ni Koria CD47 Awọn èèmọ to lagbara 40%* CD38 DAR-T Ọpọlọ Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, ati esophageal 40%* TROP2 ADC* Awọn èèmọ to lagbara 40%* * Ni Ilu China Seprehvec™ oncolytic kokoro Awọn èèmọ to lagbara; Awọn èèmọ CNS 40%* BMA ADC Awọn èèmọ olomi 20%* Bevacizumab-ADNAB™ Ọgbẹ ti ipilẹṣẹ 40%* Ni ajọṣepọ pẹlu awọn Mayo Clinic Bevacizumab-ADNAB™ Ovarian Cancer 40%* Ni ajọṣepọ pẹlu awọn Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* Ni ajọṣepọ pẹlu awọn Mayo Clinic
Awọn eto bọtini	Ifarahan	Preclinical	Igbese I	Igbese II	Ipele III/Pivotal	FDA Approval
irora
ZTlido™ 1.8% Neuralgia Postherpetic - PHN 99.8%* SP-102 (SEMDEXA) Lumbar Radicular/Irora Sciatica 82%* SP-103 (Eto Ipilẹ Lidocaine 5.4%) Irora Pada irora 20%* SP-104 (Idaduro Burst Iwọn Kekere Naltrexone) Fibromyalgia 20%* RTX (resiniferatoxin) Abẹrẹ epidural Irora ti ko le fa ni Ilọsiwaju Akàn 60.3%* Orphan yiyan RTX (resiniferatoxin) Ona-intra-articular Iwontunwonsi si Irora Orunkun Okun 60.2%*
Awọn eto bọtini	Ifarahan	Preclinical	Igbese I	Igbese II	Ipele III/Pivotal	FDA Approval
Ifijiṣẹ Lymphatic
Sofusa® egboogi-TNF Aifọwọyi (RA) 40%* Sofusa® egboogi-PD-1 Ẹjẹ T-Cell Lymphoma (CTCL) 40%* Sofusa® egboogi-CTLA-4 Melanoma 40%* Ni ajọṣepọ pẹlu awọn Mayo Clinic

Awọn eto COVID-19
Awọn eto bọtini (Itọkasi)	alakoso
COVISTIX™ (aisan ayẹwo) FDA EUA COVIMARK™ (aisan ayẹwo) FDA EUA COVISHIELD™ (itọju) PH I COVISHIELD™ (itọju) Preclinical FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III Inhibitor Mpro (ògùn ẹnu) (agbogun ti gbogun ti) Ph I Omicron mRNA ajesara (ajesara) Preclinical

ajẹsara
Awọn eto bọtini (Itọkasi)	alakoso
FUJOVEE™ (Abivertinib) (NSCLC) Ph III FUJOVEE™ (Abivertinib) (Awọn lymphomas sẹẹli B) Ph II FUJOVEE™ (Abivertinib) (Prostate) Preclinical FUJOVEE™ (Abivertinib) ( Lupus) Preclinical FUJOVEE™ (Abivertinib) (MS) Preclinical FUJOVEE™ (Abivertinib) (GvHD) Preclinical PD-L1 (Socazolimab)*(SCLC) Ph III PD-L1 (STI-3031)** (Akàn Akàn) Ph III CD47 (Awọn èèmọ to lagbara) Ph I CD38 DAR-T (Ọpọ Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, ati esophageal) Ph I TROP2 ADC* (Awọn èèmọ to lagbara) Ph I Seprehvec™ oncolytic kokoro (Awọn èèmọ to lagbara; Awọn èèmọ CNS) PH I BMA ADC (Awọn èèmọ olomi) Preclinical Bevacizumab-ADNAB™ (Akàn Endometrial) Ph I Bevacizumab-ADNAB™ (Akàn Ovarian) Ph I Rituximab-ADNAB™ (Lymphomas B-cell) Ph I

irora
Awọn eto bọtini (Itọkasi)	alakoso
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval SP-102 (SEMDEXA) Ph III SP-103 (Eto Ipilẹ Lidocaine 5.4%) Preclinical SP-104 (Idaduro Burst Iwọn Kekere Naltrexone) Preclinical RTX (resiniferatoxin) Abẹrẹ apọju (Irora ti ko le fa ninu akàn To ti ni ilọsiwaju) Ph II RTX (resiniferatoxin) ipa-ọna inu-articular (Iwọntunwọnsi si Irora Orunkun OA lile) Ph II

Ifijiṣẹ Lymphatic
Awọn eto bọtini (Itọkasi)	Igbese II
Sofusa® egboogi-TNF (Autoimmune RA) Ph I Sofusa® egboogi-PD-1 T-Cell Lymphoma (CTCL)) Ph I Sofusa® egboogi-CTLA-4 (Melanoma) Ph I